5 FDA Decisions in August Could Reshape Trading: MRNA, LNTH, BMY, CAPR, and RARE

August's FDA calendar looks more like a schedule than a surprise box

August is less a wildcard month than a graded series of regulatory decision points. Moderna's PDUFA date is August 5, 2026, and approval could bring the first mRNA-based flu shot to market. That makes the opening decision important not just for MRNA, but for how investors read the broader mRNA vaccine field.

The five catalysts fall into three rough buckets:

• Tier 1 - Moderna: Big implication if approved, especially after the FDA advisory panel voted unanimously in favor. The debate is not fully settled, though, because regulators previously raised concerns about risks in older adults.
• Tier 2 - BMY and LNTH: More straightforward execution catalysts. BMY's iberdomide application carries Priority Review and Breakthrough Therapy Designation, while Lantheus has a set PDUFA milestone on August 13, 2026.
• Tier 3 - CAPR and RARE: Rare-disease optionality with potentially sharp upside, but still the kind of setup where the trading can look more binary than foundational.

The practical edge is timing. Once the first verdicts hit, the market will start repricing the rest of the month's schedule.

Moderna could decide the tone for August biotech trading

Moderna is the clearest control group for the month because this decision says something about more than one flu season. If approved, it would be the first mRNA-based flu shot to reach market, which could strengthen confidence in the mRNA platform beyond the company's current product mix.

What the evidence supports

The near-term case is concrete. The FDA advisory committee voted unanimously in favor, and the expert panel voted unanimously in favor of the vaccine. But the review still has to resolve concerns tied to older populations, including earlier regulatory questions about risks in older adults.

Why the label may matter more than a simple yes-or-no

Moderna is seeking traditional approval for the shot...for adults 50 to 64 years old, and an accelerated approval...for adults 65 and older. That suggests a negotiated path to market rather than a clean, unrestricted approval. The company has also agreed to run an additional study and submit more data in adults 65 and older if it gets approval for that age group.

That matters for trading. A narrower or conditional label would still allow the product to reach market while reducing friction with regulators. If the FDA stops short of even that, investors may read the decision as a sign that regulatory hurdles for mRNA vaccines are tougher than expected.

BMY and LNTH look more like execution catalysts

Bristol Myers Squibb and Lantheus still have meaningful FDA events in August, but these look closer to milestone trades than platform-changing verdicts. BMY's iberdomide application has Priority Review and a target action date of August 17, 2026. Lantheus has its PDUFA target date set for August 13, 2026.

For investors, the appeal here is cleaner timing and simpler positioning: did the company clear the scheduled regulatory checkpoint, or not?

CAPR and RARE offer rare-disease optionality, not core certainty

Capricor remains tied to August timelines as well. The company says its BLA is supported by the Company's Phase 2 HOPE-2 trial and long-term outcomes from the HOPE-2-OLE trial, as well as positive results from the Phase 3 HOPE-3 trial, and the broader approval timeline still centers on a PDUFA target action date of August 22, 2026.

That keeps CAPR - and, by extension, RARE if it is part of the same August biotech narrative - in the optionality bucket. These are the names where a positive result can move the stock sharply, but where the investment case still depends more on trial data and regulatory narrative than on near-term, settled commercial evidence.

How to watch the sequence without mixing up the stakes

The cleanest way to frame the month is to separate catalyst types:

• Moderna: platform signal plus commercial upside if the label is workable.
• BMY / LNTH: execution checks against already-scheduled decision dates.
• CAPR / RARE: higher-variance rare-disease optionality tied to ongoing review and data support.

Treat Moderna as the opening indicator. If it clears, August likely ends up looking like a month when mRNA and broader biotech sentiment improved. If it stumbles, the rest of the calendar still matters, but the market may spend more time focusing on regulatory friction than on platform promise.